NDAORALTABLET
Approved
Dec 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DIUPRES-250 (chlorothiazide; reserpine) by Merck & Co. is clinical pharmacology: the mechanism of the antihypertensive effect of thiazides is unknown. Approved for pregnancy, just, heart failure and 2 more indications. First approved in 1958.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIUPRES-250 is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (an antihypertensive agent) approved in 1958 for hypertension and heart failure. Chlorothiazide increases sodium and chloride excretion in the distal renal tubule, while reserpine works through an undisclosed mechanism to lower blood pressure. The combination targets patients requiring dual antihypertensive therapy with diuretic support.
LOE Approaching
This product is in terminal lifecycle with no active Part D market data; commercial teams are likely minimal or transitioning to competitor portfolios.
Mechanism of Action
CLINICAL PHARMACOLOGY: The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are…
Indications (5)
Worked on DIUPRES-250 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.